Search
Avatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigationalAvatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby … [A33095] Thrombocytopenia is a common complication in patients suffering from chronic liver disease, occurring as a result of liver disease or a consequence of interferon-based antiviral therapy.
Lemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigational[L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … beginning of a new wave of treatment options for patients suffering from insomnia.
VidPrevtyn Beta
go.drugbank.com/drugs/DB16427Approved[L49691] It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from … VidPrevtyn Beta is an adjuvanted, recombinant COVID-19 vaccine developed collaboratively by GlaxoSmithKline (GSK) and Sanofi Pasteur.
Ranolazine
go.drugbank.com/drugs/DB00243ApprovedInvestigational[L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440] … [A189234] Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms.
Products: RAZİNA 1000 MG UZATILMIŞ SALIMLI TABLET, 60 ADET, RAZİNA 375 MG UZATILMIŞ SALIMLI TABLET, 60 ADETUridine triacetate
go.drugbank.com/drugs/DB09144Approvedde novo pyrimidine biosynthetic pathway. … Additionally, orotic acid from the de novo pyrimidine pathway that cannot be converted to UMP is excreted in the urine, accounting for the common name of the disorder, orotic aciduria.
Tipiracil
go.drugbank.com/drugs/DB09343ApprovedInvestigational[A31255] TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, or with an anti-VEGF … Tipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102.
Categories: MATE 1 Substrates with a Narrow Therapeutic Index, OCT2 Substrates with a Narrow Therapeutic IndexEltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based
Products: REVOLADE 12.5 MG FİLM TABLET, 14 ADET, ROMPAG 25 MG FİLM KAPLI TABLET, 14 ADETMepolizumab
go.drugbank.com/drugs/DB06612ApprovedInvestigationalMepolizumab was first approved by the FDA on November 4, 2015, as an add-on therapy for severe asthma and marketed under the brand name Nucala by GlaxoSmithKline. … Activated eosinophils further stimulate an inflammatory response and also induce tissue lesions and promote fibrosis, all of which contribute to the multifactorial symptomatology of hypereosinophilic diseases
Products: Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör (1 adet), Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör (3 adet)Flortaucipir F-18
go.drugbank.com/drugs/DB14914ApprovedInvestigational[A203933] It is used as a marker in positron emission tomography (PET) imaging of patients suspected of having Alzheimer's disease. … , as well as to regions containing high levels of melanin, neuromelanin, and iron.
Categories: Compounds used in a research, industrial, or household setting, Diagnostic Uses of ChemicalsSynonyms: Flortaucipir F 18Ertugliflozin
go.drugbank.com/drugs/DB11827ApprovedInvestigationalErtugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus.